You might also like
AbbVie Inc. is a global, diversified research-based biopharmaceutical company with leadership positions across several therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care . The company operates as a single global business segment dedicated to the research, development, manufacturing, commercialization, and sale of innovative medicines and therapies . AbbVie's product portfolio includes blockbuster products such as Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, Juvederm, Vraylar, Ubrelvy, and Qulipta, among others .
- Immunology - Develops and markets treatments for autoimmune diseases, with key products including Humira, Skyrizi, and Rinvoq.
- Oncology - Focuses on cancer treatment solutions, featuring products like Imbruvica and Venclexta.
- Neuroscience - Offers therapies for neurological disorders, with significant products such as Vraylar and Botox Therapeutic.
- Aesthetics - Provides cosmetic products and treatments, including Botox and Juvederm.
- Eye Care - Engages in the development and sale of treatments for various eye conditions.
-
Given the ongoing economic challenges in China that have significantly impacted Juvederm's performance, particularly within the Aesthetics segment, what specific strategies does AbbVie have to navigate these headwinds and stimulate growth in this critical market?
-
With the recent $100 million downward adjustment in VRAYLAR's full-year sales guidance due to channel mix pressures and negative pricing impact, can you elaborate on the factors leading to this shift and how you plan to mitigate similar issues moving forward?
-
In the competitive immunology space, your head-to-head trial of SKYRIZI against ENTYVIO aims for potential superiority in endoscopic improvement for ulcerative colitis patients; what gives you confidence in achieving this outcome, and what are the implications if the trial does not meet its superiority endpoints?
-
As SKYRIZI and RINVOQ continue to drive significant growth, what challenges do you foresee in maintaining their momentum across existing indications, and how do you plan to address potential competition from new market entrants and evolving treatment paradigms?
-
With the integration of Cerevel Therapeutics and the upcoming pivotal study readouts for emraclidine in schizophrenia, how is AbbVie preparing to compete against existing therapies, especially considering recent approvals with safety considerations like hepatic monitoring, and what are your expectations regarding emraclidine's safety and efficacy profile?
Competitors mentioned in the company's latest 10K filing.
- Anti-TNF products: Compete with AbbVie's immunology products .
- JAK inhibitors: Compete with AbbVie's immunology products .
- BTK inhibitors: Compete with AbbVie's oncology products .
- Biosimilars: Compete with AbbVie's biologic products, including Humira .
- Generic pharmaceutical products: Create competitive pressures on AbbVie's products that do not have patent protection .
- Orally administered products: Compete with AbbVie's biologics .
- Other companies developing products positioned as competitors to Botox: Compete in the aesthetics market .
| Customer | Relationship | Segment | Details |
|---|---|---|---|
McKesson Corporation | Wholesale distribution | All | Less than 39% of 2023 U.S. gross revenues; part of 81% of total net accounts receivable in 2023 combined across the three wholesalers. |
Cardinal Health, Inc. | Wholesale distribution | All | Less than 39% of 2023 U.S. gross revenues; part of 81% of total net accounts receivable in 2023 combined across the three wholesalers. |
AmerisourceBergen Corporation | Wholesale distribution | All | Less than 39% of 2023 U.S. gross revenues; part of 81% of total net accounts receivable in 2023 combined across the three wholesalers. |
Recent developments and announcements about ABBV.
Financial Reporting
- 2024 Results: AbbVie reported full-year adjusted earnings per share of $10.12, exceeding initial guidance by $0.49. Total net revenues were $56.3 billion, surpassing initial guidance by over $2 billion.
- Q4 Results: Adjusted earnings per share for Q4 were $2.16, $0.08 above the guidance midpoint. Total net revenues for the quarter were $15.1 billion, reflecting 6.1% operational growth.
- Revenue and Earnings: AbbVie expects total net revenues of approximately $59 billion, with adjusted earnings per share guidance between $12.12 and $12.32.
- Key Products: Skyrizi and Rinvoq are projected to generate nearly $24 billion in combined revenue in 2025, reflecting growth of over $6 billion. Neuroscience sales are expected to reach $10 billion, and oncology sales are forecasted at $6.3 billion.
- Immunology: Skyrizi and Rinvoq continue to drive growth, with strong performance across all approved indications. AbbVie anticipates further market share gains and new indications for these drugs.
- Oncology: The company is optimistic about its oncology pipeline, including assets like VENCLEXTA, ELAHERE, and Teliso-V. Regulatory submissions and approvals are expected for key programs in 2025.
- Aesthetics: While the aesthetics segment faced challenges due to market conditions in the U.S. and China, AbbVie expects gradual recovery and high single-digit revenue CAGR through 2029. The reinstatement of the original Alle loyalty program has been positively received by providers.
- Medicare Part D Impact: AbbVie noted a 4% net unfavorable impact on revenue growth due to the Medicare Part D redesign but highlighted that volume offsets are modest.
- Aesthetics Market Dynamics: Management acknowledged both headwinds and tailwinds from the growing obesity drug market, emphasizing long-term opportunities for injectables like BOTOX and Juvederm.
- Pipeline and Innovation: AbbVie is advancing its pipeline with over 20 early-stage deals signed since 2024, focusing on immunology, oncology, and neuroscience. Key upcoming milestones include regulatory submissions for Rinvoq in GCA and Teliso-V for lung cancer.
- Net Revenues: $15.102 billion, a 5.6% increase on a reported basis and 6.1% increase on an operational basis.
- Adjusted Diluted EPS: $2.16, reflecting an unfavorable impact of $0.88 per share due to acquired IPR&D and milestones expense.
- GAAP Diluted Loss Per Share: $(0.02), inclusive of a $3.5 billion intangible asset impairment charge related to emraclidine.
-
Immunology Portfolio: $7.294 billion in global net revenues, a 4.9% increase on a reported basis.
- Skyrizi: $3.778 billion, up 57.7%.
- Rinvoq: $1.834 billion, up 46.2%.
- Humira: $1.682 billion, down 49.1% due to U.S. loss of exclusivity.
-
Oncology Portfolio: $1.691 billion, a 12.0% increase.
- Venclexta: $655 million, up 11.0%.
- Imbruvica: $848 million, down 6.2%.
-
Neuroscience Portfolio: $2.509 billion, a 19.8% increase.
- Botox Therapeutic: $873 million, up 12.5%.
- Vraylar: $924 million, up 17.1%.
-
Aesthetics Portfolio: $1.298 billion, a 5.2% decrease.
- Botox Cosmetic: $687 million, down 4.2%.
- Juvederm: $279 million, down 16.3%.
- Net Revenues: $56.334 billion, a 3.7% increase on a reported basis and 4.6% increase on an operational basis.
- Adjusted Diluted EPS: $10.12, down 8.9%.
- Immunology Portfolio: $26.682 billion, up 2.1%.
- Skyrizi: $11.718 billion, up 50.9%.
- Rinvoq: $5.971 billion, up 50.4%.
- Adjusted Diluted EPS: Expected to range between $12.12 and $12.32, excluding any unfavorable impact from acquired IPR&D and milestones expense.
- Immunology Growth: Skyrizi and Rinvoq continue to drive growth, with combined 2027 revenue projections raised to over $31 billion.
- Humira Decline: U.S. revenues fell sharply due to biosimilar competition following loss of exclusivity.
- Aesthetics Challenges: Declines in Botox Cosmetic and Juvederm revenues reflect competitive pressures and market dynamics.
- Pipeline Updates: AbbVie completed acquisitions of Aliada Therapeutics and Nimble Therapeutics, strengthening its neuroscience and immunology pipelines.
- Adjusted Diluted EPS Range: $2.06 to $2.10, including the impact of $1.6 billion in acquired IPR&D and milestones expense. This represents an unfavorable impact of $0.88 per share on both GAAP and adjusted non-GAAP diluted EPS.
- Adjusted Diluted EPS Range: $10.02 to $10.06, reflecting the inclusion of $2.757 billion in acquired IPR&D and milestones expense for the year. This also includes the $0.88 per share impact from the fourth quarter.
- The acquired IPR&D and milestones expense stems from collaborations, licensing agreements, and other asset acquisitions. AbbVie does not forecast these expenses due to their uncertain timing and occurrence.
- The guidance reflects a downward adjustment from previously announced figures, which excluded these expenses.
Earnings Call
AbbVie recently released its earnings call transcript, providing key insights into its financial performance, forward guidance, and strategic initiatives. Here are the highlights:
Financial Performance
Forward Guidance for 2025
Strategic Initiatives and Market Conditions
Analyst Questions and Management Responses
Key Takeaways
AbbVie is well-positioned for robust growth in 2025 and beyond, driven by its strong immunology portfolio, expanding oncology pipeline, and recovery in the aesthetics market. The company remains focused on innovation and external business development to sustain long-term growth.
For more detailed financial metrics and strategic insights, refer to the full earnings call transcript.
Earnings Report
AbbVie (ABBV) Fourth-Quarter and Full-Year 2024 Earnings Results
AbbVie has released its financial results for the fourth quarter and full year ending December 31, 2024. Below are the key highlights:
Fourth-Quarter 2024 Highlights
Portfolio Performance
Full-Year 2024 Highlights
2025 Guidance
Significant Trends and Developments
For more details, visit AbbVie’s Investor Relations website or refer to the full press release.
Earnings Report
AbbVie Inc. has released its earnings guidance for the fourth quarter and full year of 2024, incorporating the impact of acquired in-process research and development (IPR&D) and milestones expense. Below are the key highlights:
Fourth Quarter 2024 Guidance
Full-Year 2024 Guidance
Significant Trends
This update provides insight into AbbVie's financial performance and the impact of strategic investments in research and development. The final results for Q4 2024 are still subject to financial statement closing procedures and may differ from these preliminary estimates.
Corporate Leadership
Leadership Change
Kevin K. Buckbee is leaving his role as Senior Vice President, Controller at AbbVie, planning to retire effective March 1, 2025. David R. Purdue will step up as the new Senior Vice President, Controller on the same date. Purdue has been with AbbVie since 2003 and has held various finance roles .